RFM.STU Sensorion SA
- Market cap
- EUR 470M
- P/E
- -
- P/B
- 1.09x
- ROE
- -66.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is RFM.STU undervalued?
Graham numberThe Graham number of Sensorion SA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sensorion SA fundamental analysis
No fundamental analysis for Sensorion SA yet.
Sensorion SA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sensorion SA
Sensorion SA, a biotechnology company, develops drug candidates for the treatment of inner ear disorders in France. Its pipeline includes various products in the development stage for restoring, treating, and preventing inner ear related disorders. The company's product portfolio includes SENS-401 SSNHL, which has completed Phase 2 clinical trial for the treatment of Sudden Sensorineural Hearing Loss; SENS-401 CIO that is in Phase 2 clinical trial for the treatment of Cispla…
Full company profileSensorion SA financial statements
Sensorion SA annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 1.92M | 330K | 140K | 0.00 | 0.00 | 0.00 |
| Operating Income | -8.87M | -15.0M | -23.1M | -22.3M | -28.4M | -30.8M |
| EBITDA | - | - | -22.3M | -21.5M | -25.4M | -29.0M |
| Net Income | -8.98M | -15.1M | -23.2M | -22.1M | -26.0M | -29.4M |
| EPS | -0.11 | -0.19 | -15 | -5.90 | -4.32 | -4.90 |
| Balance Sheet | ||||||
| Total Assets | 67.9M | 59.1M | 38.9M | 46.5M | 89.3M | 57.9M |
| Total Liabilities | 9.52M | 15.0M | 17.1M | 13.2M | 17.1M | 13.4M |
| Shareholders' Equity | 58.4M | 44.1M | 21.9M | 33.3M | 72.1M | 44.5M |
| Cash & Short-term Investments | 62.2M | 50.0M | 26.2M | 37.0M | 66.8M | 47.5M |
| Cash Flow | ||||||
| Operating Cash Flow | -5.31M | -10.8M | -21.4M | -21.1M | -21.3M | -27.3M |
| Capital Expenditure | 165K | 653K | 1.51M | 869K | 1.12M | 756K |
| Free Cash Flow | -5.48M | -11.4M | -22.9M | -21.9M | -22.5M | -28.0M |
| Ratios | ||||||
| ROE | -15.4% | -34.4% | -106.0% | -66.3% | -36.0% | -66.2% |
| ROA | -13.2% | -25.6% | -59.6% | -47.4% | -29.1% | -50.8% |
| Net Profit Margin | -468.7% | -4,587.9% | -16,572.0% | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Sensorion SA dividends
Sensorion SA has not paid dividends in the last 7 fiscal years.
Last stock split: 1:50 on Sep 15, 2026.
Who owns Sensorion SA
- Insiders 34.76%
- Institutions 35.51%
- Public & others 29.73%
- Shares outstanding 515M
- Free float 75.1M
Sensorion SA company profile
- Company name
- Sensorion SA
- Ticker
- RFM.STU
- Exchange
- Stuttgart Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 61
- Fiscal year end
- December
- Address
- 375, rue du Professeur Joseph Blayac, Montpellier, France, 34080
- Phone
- 33 4 67 20 77 30
- Website
- sensorion.com
About Sensorion SA
Sensorion SA, a biotechnology company, develops drug candidates for the treatment of inner ear disorders in France. Its pipeline includes various products in the development stage for restoring, treating, and preventing inner ear related disorders. The company's product portfolio includes SENS-401 SSNHL, which has completed Phase 2 clinical trial for the treatment of Sudden Sensorineural Hearing Loss; SENS-401 CIO that is in Phase 2 clinical trial for the treatment of Cisplatin-Induced Ototoxicity; and SENS-401 Cochlear, which is in Phase 2 clinical trial for the treatment of hearing preservation after cochlear implantation. It is also developing OTOF-GT (SENS-501), a gene therapy development program that has completed Phase 1 clinical trial to restore hearing in people living with Otoferlin deficiency; and GJB2-GT, a gene therapy development program, which is in pre-clinical trial to restore hearing in people living with hearing loss due to mutations in the GJB2 gene. The company was incorporated in 2009 and is headquartered in Montpellier, France.
Sensorion SA management
7- Mr. Frederic Chereau M.B.A.Chief Executive Officer · born 1967
- Ms. Laurene DanonChief Financial Officer
- Mr. Bernd SchmidtChief Technical Officer
- Ms. Christine Le BecHead of CMC Gene Therapy
- Ms. Stephanie FilipeHead of Business Operations & Portfolio Management
- Mr. Laurent DesireHead of Preclinical Development
- Ms. Rachel CooperHead of Audiology